Complement Component 9 (C9) is the final, pore-forming subunit of the Membrane Attack Complex (MAC) in the terminal complement pathway. Targeted inhibition of C9 represents a highly strategic therapeutic avenue for complement-mediated disorders, neurodegenerative diseases, and transplant rejection, offering the distinct advantage of blocking terminal lytic activity while preserving upstream opsonization (C3b-mediated clearance) and immunomodulatory signaling.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for C9 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | C9 Recombinant Protein (Human/Cyno/Mouse orthologs) HEK293 expressed (Native Glycosylation), High purity (>95%), Endotoxin Controlled (<1 EU/ug). Sequence Verified. |
View C9 Products |
| Gene Delivery | C9 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and target overexpression. |
View C9 Products |
| Benchmark Ab | Anti-C9 Recombinant Antibody (Biosimilar) Recombinant positive control derived from clinical-stage sequences. |
View C9 Products |
| Validator | C9 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View C9 Products |
| Related Target A | C5 (Complement Component 5) Upstream initiator of the MAC assembly pathway; key comparator for terminal pathway blockade. |
View C5 Products |
| Related Target B | CD59 (Protectin) Endogenous GPI-anchored membrane inhibitor of C9 polymerization and MAC formation. |
View CD59 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species Cyno/Mouse evaluation | Human, Mouse, and Cynomolgus ortholog C9 proteins available with >95% purity and verified theoretical MW. |
| Polymerization and conformational complexity | HEK293-expressed native-like glycosylated monomeric C9 to prevent premature auto-aggregation during assay setup. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay validation. |
| False Positives | Validated siRNA included for specificity and target knockdown verification. |
Live C9 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for C9 therapeutics is intensifying, with major players shifting focus from systemic broad-spectrum complement inhibition to tissue-specific, terminal pathway-targeted monoclonal antibodies (mAbs) and small molecules. As first-generation therapies (such as C5 inhibitors) reach clinical maturity, the next wave of R&D is targeting C9 to selectively block MAC-mediated tissue destruction in neurodegenerative diseases—such as Guillain-Barré syndrome, Myasthenia Gravis, and Amyotrophic Lateral Sclerosis (ALS)—without compromising the upstream immune clearance pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Regenesance, Annexon Biosciences | Neuromuscular & Neurodegenerative Disorders | Inhibition of C9 polymerization (Need high-purity monomeric C9 antigen) |
| Antisense Oligonucleotide / siRNA | Ionis Pharmaceuticals, Alnylam | Ocular Diseases (e.g., AMD), Renal Diseases | In vivo/In vitro knockdown validation (Need sequence-verified C9 siRNA & Lentivirus) |
| Small Molecule Inhibitors | Academic/Biotech Consortia | Chronic Inflammatory Diseases | High-throughput screening of MAC assembly (Need native-conformation C9 and C5b-8 components) |